Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: Results of a pharmacodynamic study

JACC: Cardiovascular Interventions

Volumn 5, Issue 3, 2012, Pages 293-300

  Ueno, Masafumi ^a,b   Ferreiro, José Luis ^a   Desai, Bhaloo ^a   Tomasello, Salvatore D ^a   Tello Montoliu, Antonio ^a   Capodanno, Davide ^a   Capranzano, Piera ^a   Kodali, Murali ^a   Dharmashankar, Kodlipet ^a   Charlton, Ronald K ^c   Bass, Theodore A ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b KINKI UNIVERSITY   (Japan)

^c UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

Author keywords

clopidogrel; diabetes mellitus; platelet function; smoking

Indexed keywords

CLOPIDOGREL; COTININE; PHOSPHOPROTEIN; PURINERGIC P2Y12 RECEPTOR;

ADULT; AGED; BLOOD LEVEL; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 84858754393     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2011.09.027     Document Type: Article

References (39)

1. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516 (Pubitemid 46517957)
2. J.L. Ferreiro, D.J. Angiolillo Clopidogrel response variability: current status and future directions Thromb Haemost 102 2009 7 14
3. N.A. Farid, A. Kurihara, S.A. Wrighton Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans J Clin Pharmacol 50 2010 126 142
4. S. Zevin, N.L. Benowitz Drug interactions with tobacco smoking: an update Clin Pharmacokinet 36 1999 425 438 (Pubitemid 29317490)
5. E.R. Bates, W.C. Lau, D.J. Angiolillo Clopidogrel-drug interactions J Am Coll Cardiol 57 2011 1251 1263
6. K.P. Bliden, J. Dichiara, L. Lawal The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 52 2008 531 533
7. K.Y. Saraff, S.R. Steinhubl, A.P. Hsu, E.J. Topol Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following percutaneous coronary intervention (abstr) J Am Coll Cardiol 47 2006 36B
8. N.R. Desai, J.L. Mega, S. Jiang, C.P. Cannon, M.S. Sabatine Interaction between cigarette smoking and clinical benefit of clopidogrel J Am Coll Cardiol 53 2009 1273 1278
9. J.S. Berger, D.L. Bhatt, S.R. Steinhubl CHARISMA Investigators Smoking, clopidogrel, and mortality in patients with established cardiovascular disease Circulation 120 2009 2337 2344
10. M.A. Wall, J. Johnson, P. Jacob, N.L. Benowitz Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers Am J Public Health 78 1988 699 701
11. D. Erlinge, C. Varenhorst, O.O. Braun Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo J Am Coll Cardiol 52 2008 1968 1977
12. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913 (Pubitemid 36736631)
13. M.J. Price, P.B. Berger, P.S. Teirstein GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
14. G. Campo, G. Parrinello, P. Ferraresi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: relationship with gene polymorphisms and clinical outcomes J Am Coll Cardiol 57 2011 2474 2483
15. D.J. Angiolillo, S.B. Shoemaker, B. Desai Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Anti-Platelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 2007 708 716 (Pubitemid 46294761)
16. D.J. Angiolillo, P. Capranzano, S. Goto A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur Heart J 29 2008 2202 2211
17. D.J. Angiolillo, J.J. Badimon, J.F. Saucedo A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 trial Eur Heart J 32 2011 838 846
18. U.E. Ziegler, J. Kauczok, U.A. Dietz, H.B. Reith, K. Schmidt Clinical correlation between the consumption of nicotine and cotinine concentrations in urine and serum by competitive enzyme-linked immunosorbent assay Pharmacology 72 2004 254 259 (Pubitemid 39482695)
19. N.L. Benowitz, J.T. Bernert, R.S. Caraballo, D.B. Holiday, J. Wang Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004 Am J Epidemiol 169 2009 236 248
20. J. Sudbø, R. Samuelsson, B. Risberg Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling J Clin Oncol 23 2005 1927 1933 (Pubitemid 46211371)
21. M.K. Hellerstein, N.L. Benowitz, R.A. Neese Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers J Clin Invest 93 1994 265 272 (Pubitemid 24030845)
22. L. Bonello, U.S. Tantry, R. Marcucci Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
23. M. Valgimigli, G. Campo, N. de Cesare 3T/2R Investigators Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 2009 3215 3222
24. J.L. Ferreiro, D. Sibbing, D.J. Angiolillo Platelet function testing and risk of bleeding complications Thromb Haemost 103 2010 1128 1135
25. S.D. Wiviott, E. Braunwald, C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
26. L. Wallentin, R.C. Becker, A. Budaj PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
27. I. Tantcheva-Poór, M. Zaigler, S. Rietbrock, U. Fuhr Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test Pharmacogenetics 9 1999 131 144 (Pubitemid 29358995)
28. G. Shanker, J.L. Kontos, D.M. Eckman, D. Wesley-Farrington, D.C. Sane Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts J Thromb Thrombolysis 22 2006 213 220 (Pubitemid 44857783)
29. M. Sibbald, A.T. Yan, W. Huang Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events Am Heart J 160 2010 855 861
30. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 54 2005 2430 2435 (Pubitemid 41134272)
31. D.J. Angiolillo, E. Bernardo, M. Sabaté Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 2007 1541 1547 (Pubitemid 47532327)
32. J.L. Ferreiro, D.J. Angiolillo Diabetes and antiplatelet therapy in acute coronary syndrome Circulation 123 2011 798 813
33. 12 receptor signaling pathway in patients with type 2 diabetes mellitus and coronary artery disease Thromb Haemost 105 2011 730 732
34. K.W. Park, J.J. Park, K.H. Jeon Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status Arterioscler Thromb Vasc Biol 31 2011 665 671
35. I.S. Ockene, N.H. Miller American Heart Association Task Force on Risk Reduction Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association Circulation 96 1997 3243 3247 (Pubitemid 27500133)
36. S.C. Smith Jr., J. Allen, S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update J Am Coll Cardiol 47 2006 2130 2139 (Pubitemid 44275145)
37. CAPRIE Steering Committee A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) Lancet 348 1996 1329 1339
38. D.L. Bhatt, S.P. Marso, A.T. Hirsch, P.A. Ringleb, W. Hacke, E.J. Topol Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 90 2002 625 628 (Pubitemid 35264538)
39. P.A. Ringleb, D.L. Bhatt, A.T. Hirsch CAPRIE Investigators Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events Stroke 35 2004 528 532 (Pubitemid 38174442)